Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | HTR1A | P08908 | 4/20 | 0.50 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8102565 | 0.95 | MAOB (0.50) | MAOBHTR1ADRD2DRD3 | |
| SCHEMBL8092753 | 0.89 | DRD2 (0.49) | MAOBHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL31491133 | 0.79 | HTR1A (0.48) | MAOBHTR1A | |
| SCHEMBL6953084 | 0.78 | MAOB (0.62) | MAOBHTR1A | |
| SCHEMBL6946848 | 0.78 | MAOB (0.71) | MAOBHTR1ADRD2DRD3 | |
| SCHEMBL30022123 | 0.78 | POLB (0.54) | — | |
| Hydrochloric Acid SCHEMBL31491177 | 0.76 | SIGMAR1 (0.43) | MAOBHTR1A | |
| SCHEMBL14028451 | 0.75 | HTR1A (0.79) | MAOBHTR1ADRD2DRD3 | |
| SCHEMBL7688505 | 0.74 | KDM4E (0.65) | HTR1AKDM4ELMNADRD2DRD3 | |
| SCHEMBL45324 | 0.73 | ALDH1A1 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346983-A3 | Phthalimido arylpiperazines as alpha 1A receptor antagonists useful in the treatment of benign prostatic hyperplasia | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1346983-A2 | Phthalimido arylpiperazines as alpha 1A receptor antagonists useful in the treatment of benign prostatic hyperplasia | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-09-24 | — | — | EP | disclosed |